These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29487254)

  • 1. Histological transformation of adenocarcinoma to small cell carcinoma lung as a rare mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors: Report of a case with review of literature.
    Hui M; Uppin SG; Stalin BJ; Sadashivudu G
    Lung India; 2018; 35(2):160-163. PubMed ID: 29487254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to epithelial growth factor receptor tyrosine kinase inhibitors in a patient with transformation from lung adenocarcinoma to small cell lung cancer: A case report.
    Fang L; He J; Xia J; Dong L; Zhang X; Chai Y; Li Y; Niu M; Hang T; Li S
    Oncol Lett; 2017 Jul; 14(1):593-598. PubMed ID: 28693210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transformation of
    Miyamoto K; Ogino H; Kakimoto T; Matsumura Y; Haji K; Mitsuhashi A; Morita Y; Tsukazaki Y; Yabuki Y; Ozaki R; Yoneda H; Sato S; Hanibuchi M; Bando Y; Nokihara H; Nishioka Y
    Respir Med Case Rep; 2024; 51():102076. PubMed ID: 39027818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced Lung Adenocarcinoma with EGFR 19-del Mutation Transformed into SCC after EGFR-tyrosine Kinase inhibitors Treatment: A Case report.
    Ji XZ; Liu ZD; Ye YP; Li Q; Liu XJ; Zhou MH; Jin Y
    World J Clin Cases; 2024 Jul; 12(20):4405-4411. PubMed ID: 39015891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transformation From Adenocarcinoma to Pleomorphic Carcinoma as an Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Nishimatsu K; Minami S; Ihara S; Yasuoka H
    J Med Cases; 2021 Aug; 12(8):310-314. PubMed ID: 34434479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor.
    Kim WJ; Kim S; Choi H; Chang J; Shin HJ; Park CK; Oh IJ; Kim KS; Kim YC; Choi YD
    Thorac Cancer; 2015 Nov; 6(6):800-4. PubMed ID: 26557922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case report: small cell transformation and metastasis to the breast in a patient with lung adenocarcinoma following maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
    Lin Q; Cai GP; Yang KY; Yang L; Chen CS; Li YP
    BMC Cancer; 2016 Aug; 16():593. PubMed ID: 27488410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Advances in the Transformation to Small Cell Lung Cancer from Non-small Cell Lung Cancer Following Acquired Drug-resistance to EGFR Tyrosine Kinase Inhibitors].
    Zhang W; Li Y; Wu D
    Zhongguo Fei Ai Za Zhi; 2017 Oct; 20(10):720-726. PubMed ID: 29061221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transformation to large cell neuroendocrine carcinoma as acquired resistance mechanism of EGFR tyrosine kinase inhibitor.
    Kogo M; Shimizu R; Uehara K; Takahashi Y; Kokubo M; Imai Y; Tomii K
    Lung Cancer; 2015 Nov; 90(2):364-8. PubMed ID: 26384434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C
    J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transformation of adenocarcinoma to squamous cell carcinoma as a source of EGFR-TKI resistance: A case report and literature review.
    Xi YZ; Xie L; Tan XW; Zeng SL
    Front Oncol; 2022; 12():942084. PubMed ID: 36158654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases.
    Ahn S; Hwang SH; Han J; Choi YL; Lee SH; Ahn JS; Park K; Ahn MJ; Park WY
    J Pathol Transl Med; 2016 Jul; 50(4):258-63. PubMed ID: 27160687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report.
    Taniguchi Y; Horiuchi H; Morikawa T; Usui K
    Case Rep Oncol; 2018; 11(2):323-329. PubMed ID: 29928211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.
    Minari R; Bordi P; Tiseo M
    Transl Lung Cancer Res; 2016 Dec; 5(6):695-708. PubMed ID: 28149764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors.
    Shao Y; Zhong DS
    Int J Clin Oncol; 2018 Apr; 23(2):235-242. PubMed ID: 29110101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
    De Pas T; Toffalorio F; Manzotti M; Fumagalli C; Spitaleri G; Catania C; Delmonte A; Giovannini M; Spaggiari L; de Braud F; Barberis M
    J Thorac Oncol; 2011 Nov; 6(11):1895-901. PubMed ID: 21841502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.
    Suda K; Murakami I; Sakai K; Mizuuchi H; Shimizu S; Sato K; Tomizawa K; Tomida S; Yatabe Y; Nishio K; Mitsudomi T
    Sci Rep; 2015 Sep; 5():14447. PubMed ID: 26400668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transformation to small cell lung cancer as an acquired resistance mechanism in EGFR-mutant lung adenocarcinoma: a case report of complete response to etoposide and cisplatin.
    Hwang KE; Jung JW; Oh SJ; Park MJ; Shon YJ; Choi KH; Jeong ET; Kim HR
    Tumori; 2015 Jun; 101(3):e96-8. PubMed ID: 25908039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.